Whilst vaccination remains the most important intervention to prevent serious outcomes in people who get COVID-19, some people, even when vaccinated, are at high risk of hospitalisation, intensive care admission and death. Therapeutics now exist that can be given early, ideally within the first five days, to people at high risk of adverse outcomes.  Using a case study approach, this course will introduce these treatments and explain which patients are eligible and how they can access them across the UK. It will also introduce the new NICE guidance and discuss the strengths and limitations of the current approach including the importance of ensuring that the conditions associated with increased risk are coded in computerised medical records. 

Full financial support for the design and development of this eLearning module is provided by Pfizer Ltd as a corporate sponsorship project, an arm’s length agreement. Pfizer has had no involvement in the content. Editorial and content decisions were made solely by the RCGP.

Pfizer logo

Curriculum: Infectious Disease and Travel Health
Time to complete this course: 30 minutes
Date of publication: 5 June 2023
Reviewed and updated: 15 April 2024
Mode: Course
Podcast icon: No
Course index: Show
Section titles: Hide
Breadcrumb: Hide